Peptides for Perimenopause: What's Actually Worth Trying
Fatigue, brain fog, sleep disruption, weight redistribution, collagen loss — estrogen decline sets off cascades that HRT alone doesn't fully address. Here's where peptides fit and where they don't.
Perimenopause is not one event. It's a gradual hormonal transition that typically begins in the mid-to-late 40s and lasts 4–8 years, during which estrogen and progesterone fluctuate unpredictably before eventually declining. The symptoms — fatigue, brain fog, disrupted sleep, body composition changes, mood shifts, skin and hair changes — emerge because declining estrogen affects far more systems than reproduction.
Hormone replacement therapy addresses the sex hormone deficiency directly. But estrogen and progesterone aren't the only hormones that decline during this transition. Growth hormone pulsing decreases. NAD+ levels fall. Collagen production drops — approximately 30% in the first five years post-menopause. Mitochondrial function deteriorates.
Peptides target these parallel systems. The clinical framing isn't HRT or peptides — it's HRT for sex hormones AND peptides for the axes that estrogen replacement alone doesn't cover.
The Symptom-to-Peptide Map
Instead of listing peptides and asking you to find your symptom, let's start from what you're experiencing and work toward what addresses it.
| Symptom | What's Happening | Peptide(s) to Consider | Evidence Level |
|---|---|---|---|
| Fatigue & low energy | Mitochondrial decline, GH reduction, sleep disruption | NAD+, CJC-1295/Ipa, SS-31 | Moderate |
| Brain fog & cognition | Estrogen-mediated neurotransmitter changes | NAD+, Selank, CJC-1295/Ipa | Moderate |
| Sleep disruption | Declining melatonin, GH pulse disruption, hot flashes | CJC-1295/Ipa, DSIP, Epitalon | Moderate |
| Weight redistribution / belly fat | Metabolic shift, insulin resistance, visceral fat gain | Semaglutide/tirzepatide, AOD-9604, Tesamorelin | Strong (GLP-1s) |
| Skin thinning & collagen loss | Estrogen-driven collagen decline (30% in 5 years) | GHK-Cu, Glutathione | Moderate (RCTs initiated) |
| Hair thinning | Androgen sensitivity + follicle miniaturization | GHK-Cu | Emerging |
| Anxiety & mood | Estrogen decline affects serotonin/GABA signaling | Selank | Moderate (Russian data) |
| Low libido | Hormonal shifts, neurotransmitter changes | PT-141 (FDA-approved for HSDD) | Strong |
The Tier 1 Peptides: Strongest Rationale
CJC-1295 / Ipamorelin
Growth hormone pulsing declines with age, and the transition through perimenopause accelerates this decline. CJC-1295 (a growth hormone-releasing hormone analog) combined with Ipamorelin (a growth hormone secretagogue) restores the natural pulsatile GH pattern — particularly the large nocturnal pulse that governs deep sleep and tissue repair.
For perimenopausal women, the relevance is threefold: improved sleep architecture (deeper, more restorative sleep), better body composition (reduced visceral fat, maintained lean mass), and increased energy through GH-mediated metabolic effects. This is the peptide stack most commonly prescribed by integrative medicine providers for perimenopausal patients.
Key consideration: GH peptides can affect glucose metabolism. Baseline bloodwork including fasting glucose, insulin, and IGF-1 is essential. See our Energy & Longevity hub for more.
GHK-Cu (Copper Peptide)
Collagen production is directly stimulated by estrogen. When estrogen declines, collagen follows — skin loses firmness and thickness, wound healing slows, and hair follicle cycling is disrupted. GHK-Cu is a copper-binding tripeptide that stimulates collagen I, III, and elastin synthesis, promotes angiogenesis, and has demonstrated wound-healing and anti-inflammatory properties.
Three new randomized controlled trials were initiated in 2025 for GHK-Cu in wound healing and hair growth — the first significant expansion of its clinical evidence base in years. For perimenopausal collagen loss specifically, GHK-Cu addresses the structural protein deficit that estrogen decline creates. Available as injectable, topical serum, or microneedling adjunct. See our GHK-Cu profile.
NAD+ (Nicotinamide Adenine Dinucleotide)
NAD+ is a coenzyme critical for mitochondrial energy production that declines with age. The decline accelerates during menopause — glutathione depletion, which is coupled to NAD+ metabolism, also accelerates rapidly during the menopausal transition. Injectable NAD+ restores cellular energy capacity directly, bypassing the conversion steps that limit oral NAD+ precursors (NMN, NR).
For perimenopausal fatigue — the "why am I so tired even when I sleep" complaint — NAD+ targets the cellular energy machinery that's declining independently of sex hormones. It won't fix hormonal fatigue, but it addresses the mitochondrial component that HRT alone doesn't reach.
PT-141 (Bremelanotide / Vyleesi)
PT-141 is the only peptide with an FDA-approved indication specifically for women — hypoactive sexual desire disorder (HSDD) in premenopausal women. It works via melanocortin receptors in the central nervous system, separate from the hormonal pathway. It's not a hormonal treatment; it's a neurotransmitter-mediated approach to desire.
For perimenopausal women experiencing declining libido, PT-141 addresses desire through a mechanism that isn't dependent on estrogen levels — making it relevant even when hormonal therapy hasn't resolved the symptom. Available by prescription as an on-demand subcutaneous injection.
Tier 2: Worth Knowing About
- Selank — an anxiolytic peptide studied for anxiety and cognitive function. Works on GABAergic and serotonergic pathways that estrogen decline disrupts. Evidence is primarily from Russian research. Nasal spray or injection. Relevant for the anxiety/mood dimension of perimenopause.
- DSIP (Delta Sleep-Inducing Peptide) — targets sleep architecture specifically. Note: DSIP was the one peptide rejected by the PCAC in July 2026 (emideltide). Its compounding pathway is currently closed.
- Epitalon — telomere maintenance and melatonin normalization. Cleared by PCAC July 2026. The melatonin restoration component is relevant for perimenopausal sleep disruption. See our Epitalon profile.
- Glutathione — the master antioxidant. Glutathione depletion accelerates during menopause and drives visible skin aging. Injectable glutathione is used for skin brightening and systemic antioxidant support.
What to Skip
Not every peptide marketed to women in perimenopause is worth your time or money:
- Any peptide claiming to "replace" HRT — peptides don't replace estrogen and progesterone. Different systems, different mechanisms. Be wary of providers who position peptides as HRT alternatives rather than complements.
- "Anti-aging" peptide stacks with no specific targeting — a stack of five peptides with vague longevity claims isn't a perimenopause protocol. Specificity matters. Target your symptoms, not a marketing category.
- Oral collagen peptides as standalone skin therapy — dietary collagen peptides (the supplement aisle kind) may provide some benefit, but they aren't in the same evidence category as GHK-Cu for targeted collagen stimulation. They're a supplement, not a therapy.
The Bottom Line
Perimenopause disrupts multiple systems simultaneously. HRT addresses the sex hormone deficiency. Peptides target the parallel declines — growth hormone pulsing, mitochondrial energy, collagen synthesis, neurotransmitter signaling — that estrogen replacement alone doesn't cover.
Start with the symptom, not the peptide. Match the intervention to what you're actually experiencing. Get baseline bloodwork before starting anything. Work with a provider who understands both HRT and peptide therapy, because the best outcomes come from integrating both rather than choosing between them.